Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NFIL3 Biologics Sequence Review Report 2026: Nuclear factor interleukin-3-regulated protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NFIL3 Biologics Sequence Review Report 2026: Nuclear factor interleukin-3-regulated protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NFIL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NCOA7 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NCOA7 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NCOA6 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NCOA6 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NCOA3 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NCOA3 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NCOA1 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NCOA1 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NCAM2 Biologics Sequence Review Report 2026: Neural cell adhesion molecule 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NCAM2 Biologics Sequence Review Report 2026: Neural cell adhesion molecule 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCAM2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MYDGF Biologics Sequence Review Report 2026: Myeloid-derived growth factor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MYDGF Biologics Sequence Review Report 2026: Myeloid-derived growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MYDGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MST1 Biologics Sequence Review Report 2026: Hepatocyte growth factor-like protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MST1 Biologics Sequence Review Report 2026: Hepatocyte growth factor-like protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MST1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MRGPRD Biologics Sequence Review Report 2026: Mas-related G protein-coupled receptor member D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MRGPRD Biologics Sequence Review Report 2026: Mas-related G protein-coupled receptor member D Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MRGPRD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MNDA Biologics Sequence Review Report 2026: Myeloid cell nuclear differentiation antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MNDA Biologics Sequence Review Report 2026: Myeloid cell nuclear differentiation antigen Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MNDA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MLANA Biologics Sequence Review Report 2026: Melanoma antigen recognized by T-cells 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MLANA Biologics Sequence Review Report 2026: Melanoma antigen recognized by T-cells 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MLANA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MEGF9 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MEGF9 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →